AIxCrypto Holdings
-
Qualigen Therapeutics Stockholders Approve Proposals; Rebrands as AIxCrypto Holdings, Inc. (AIXC), Focuses on AI × Web3 Strategy
Qualigen Therapeutics (QLGN) shareholders approved a strategic shift to AIxCrypto Holdings (AIXC) by Nov 20, 2025. Faraday Future will become the majority shareholder (≈55% direct, ≈63% incl. affiliates) and nominate most board members before this date. The company approved share issuance, an equity incentive plan, and Nasdaq rule waivers. A new AI/Web3 business model and board will be revealed at the Nasdaq ceremony. This marks a transition from biotechnology into a decentralized AI technology platform.
